Mexico Diabetic Retinopathy Market Size & Outlook, 2025-2033
Mexico Diabetic Retinopathy Market Insights
- Reed Intelligence analysis indicates that the Mexico Diabetic Retinopathy Market size, valued at USD 144.68 Million in 2024, is expected to expand to USD 264.65 Million by 2033.
- The Mexico market is forecasted to expand at a CAGR of 7.05% spanning 2026–2033.
- Proliferative Diabetic Retinopathy held the leading position among By Type segments in 2024, based on market size.
- Non-proliferative Diabetic Retinopathy is projected to post the fastest growth rate, sustaining its position as the most attractive By Type segment during the forecast horizon.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, Mexico held 1.58% of the global Diabetic Retinopathy Market size.
- By 2033, United States is anticipated to capture the largest share of the global Diabetic Retinopathy Market.
- In LATAM, Brazil is expected to lead the regional Diabetic Retinopathy Market size by 2033.
- Chile will remain the fastest-growing market in LATAM, reaching USD 79.14 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 144.68 Million |
| Market Size In 2033 | USD 264.65 Million |
| Largest segment | Proliferative Diabetic Retinopathy |
| Units | Revenue in USD Million |
| CAGR | 7.05% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Treatment Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Mexico Diabetic Retinopathy Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | 93.75 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Mexico Diabetic Retinopathy Market By Treatment Type 2025-2033 (USD Million)
| By Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-VEGF Drug | XX.x | XX.x | XX.x | 58.03 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Steroid Implants | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Surgeries | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vitrectomy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
